SynVivo
SynVivo is a pioneering provider of cell-based microfluidic organ-on-chip platforms, delivering biologically realistic microenvironments for real-time study of cellular behavior, drug delivery, and drug discovery. Their proprietary technology bridges microfluidics and bioengineering, enabling advanced research in life sciences, disease modeling, and personalized medicine. SynVivo's chips support microvascular networks that closely mimic in vivo tissue conditions, validated by scientific research to more accurately reflect human biology than conventional culture methods. The platform is especially impactful for personalized cancer therapy, allowing patient-derived cells to be used for drug efficacy testing in a simulated tumor environment. SynVivo also distributes a wide range of high-quality primary cells and cell lines from various species, supporting research in immunology, cardiovascular, and cancer biology.
Patents
What We Do
A starter kit featuring the SynTumor Cancer-on-a-Chip with microvascular network and 8μm pillar configuration, designed for advanced cancer modeling and research.
A starter kit featuring the SynTumor Cancer-on-a-Chip with microvascular network and 2μm pores, ideal for simulating tumor microenvironments.
A starter kit with SynTumor Cancer-on-a-Chip in an idealized radial 8μm pillar configuration for cancer research applications.
A starter kit with SynTumor Cancer-on-a-Chip in an idealized radial 2μm pore configuration for advanced oncology studies.
A starter kit with SynTumor Cancer-on-a-Chip in a linear 5μm pore configuration, supporting cancer-on-chip research.
A starter kit with SynTumor Cancer-on-a-Chip in a linear 3μm pore configuration for detailed cancer microenvironment modeling.
Application Area
Vaccines
Digital Health Technologies
Services
News & Updates
A publication highlighting the use of SynVivo's platform to study the effects of the NX210c peptide on blood-brain barrier integrity.
Research article utilizing SynVivo's technology to analyze neutrophil phenotypes in sepsis patients.
Study demonstrating the use of a biomimetic chip for evaluating monoclonal antibody bioavailability, leveraging SynVivo's platform.
SynVivo will participate in the SHOCK 2025 conference in Boston.
SynVivo will attend the BIO International 2025 event in Boston.
SynVivo will be present at the MPS World Summit 2025 in Belgium.